For most stocks, a 25% cut in an analyst's target price following an earnings release would send investors scrambling for the exit door. That wasn't the case with Bluebird Bio (BLUE -6.23%), however.The clinical-stage biotech saw a decent price rise after those two events in late March. What helped was that, despite the cut, said analyst believes the shares are on track to double in price and then some.The price target is cut. However...That prognosticator is Wells Fargo's Yanan Zhu, who now feels Bluebird ...

bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Conference Call March 26, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director of IR Andrew Obenshain - CEO Tom Klima - Chief Commercial and Operating Officer Chris Krawtschuk - CFO Conference Call Participants Jason Gerberry - Bank of America Securities Danielle Brill - Raymond James Jack Allen - Baird Gena Wang - Barclays Eric Joseph - JPMorgan Mani Foroohar - Leerink Jeffrey Hung - Morgan Stanley Salveen Richter - Goldman Sachs Sami Corwin - ...

bluebird bio, Inc. (BLUE) announced that it has received a $175 million five-year, term loan facility from Hercules Capital, Inc. (HTGC) . The funding will extend bluebird’s cash runaway by two years. The company’s shares rose 1.4% on the news.Per the terms of the agreement, bluebird will get the term loans in four tranches. The first tranche of $75 million was drawn upon the closing of the transaction. BLUE will be eligible to draw two additional tranches of $25 million each, subject to the achievement of ...

Like many biotechs, Bluebird Bio's (BLUE 1.41%) stock has been volatile over its lifetime. The company, which specializes in gene-editing therapies, has struggled with high costs and limited patient populations for two of its three approved products, plus looming competition for the third. The company was thrown something of a financial lifeline on Monday, however. Cautiously optimistic investors pushed the stock's price up by 1.4% in reaction. That was good enough to beat the S&P 500 index's 0.6% bump high ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a $175 million five-year, term loan facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”). The transaction strengthens the Company’s balance sheet as it executes on the commercial launches for its three FDA approved gene therapies – LYFGENIA for sickle cell disease, ZYNTEGLO for beta-thalassemia and SKYSONA for cerebral adrenoleukodystrophy. The term lo ...

Penny stocks -- companies whose shares are trading for $5 or less -- look cheap for a reason: They have encountered severe issues, and the market has little faith that they will turn things around. That's the situation in which Bluebird Bio (BLUE -3.24%), a biotech focused on gene editing, finds itself. The company has made tremendous progress and has proven innovative abilities, but still faces severe headwinds.On the bright side, buying shares today would translate to outsized returns in the long run if t ...

Investors were clearly feeling blue about Bluebird Bio (BLUE -9.15%) on Tuesday. Collectively, they traded the commercial-stage biotech stock down by more than 9% in Tuesday's trading, not long after an analyst cut his price target on the shares. That price decline was far more dramatic than the 1% slip of the S&P 500 index on the day.A deep price cut from HSBCAfter market close on Monday, HSBC's Morten Herholt reduced his Bluebird Bio fair value assessment to $1.02 per share. That represents a 56% cut from ...

Key Pointsbluebird bio is a major beneficiary of gene therapy headlines as it has 3 FDA approval therapies.bluebird was a $158 stock in 2019, which has fallen as low as 87 cents in 2024.OTM LEAPS calls can be held while selling OTM front-month calls for income.5 stocks we like better than bluebird bioGene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT from CRISPR Therapeutics AG NASDAQ: CRSP and part ...

Key PointsHealthcare stocks quietly build momentum to bring the market's next potential rally; not all stocks are created equal.bluebird Bio stock is a particular case in this space, calling for a massive upside in price targets, and institutional buying could create the next big short squeeze. Management has set up the scene, and the writing is on the wall for its upcoming earnings announcement.5 stocks we like better than bluebird bioMaybe you are looking back at the 2020-2023 equity curve in your portfol ...

Key PointsGene therapy usually involves a one-time treatment but can cost from $2 million up to $3.5 million per patient.Like Gilead Sciences did with its hepatitis C drugs, gene therapy companies used value-based pricing to justify the high fees for novel therapies.Unlike Gilead's hepatitis C drugs, these gene therapy treatments have yet to cure rare diseases but instead care for the worst symptoms.5 stocks we like better than CRISPR TherapeuticsGene therapy treatments have been making major headlines as a ...